Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Annals of Hematology

Volumn 96, Issue 8, 2017, Pages 1253-1270

  Di Minno, Giovanni ^a   Navarro, David ^b   Perno, Carlo Federico ^c   Canaro, Mariana ^d   Gürtler, Lutz ^e   Ironside, James W ^f   Eichler, Hermann ^g   Tiede, Andreas ^h  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g SAARLAND UNIVERSITY   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bleeding disorder; Blood; Clotting; Inactivation; Infection risk; Pathogen; Patient information; Removal; Virus

Indexed keywords

AMOTOSALEN; AMUSTALINE; BLOOD CLOTTING FACTOR; GLUTATHIONE; METHYLENE BLUE; PHOTOSENSITIZING AGENT; RECOMBINANT BLOOD CLOTTING FACTOR; RECOMBINANT PROTEIN; RIBOFLAVIN; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING DISORDER; BLOOD COMPONENT; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; FILTRATION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; MEDLINE; MICROBIAL CONTAMINATION; NANOFILTRATION; NONHUMAN; PATHOGEN REDUCTION SYSTEM; PHOTODYNAMIC THERAPY; PLASMA; PRION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SOLVENT DETERGENT TREATMENT; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET C RADIATION; ULTRAVIOLET PHOTOTHERAPY; BLOOD COAGULATION DISORDERS; BLOOD SAFETY; BLOODBORNE BACTERIUM; DISINFECTION; HEMORRHAGIC DISORDERS; ISOLATION AND PURIFICATION; PROCEDURES; RISK ASSESSMENT; SEPSIS; STANDARDS;

BLOOD COAGULATION DISORDERS; BLOOD SAFETY; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; DISINFECTION; HEMORRHAGIC DISORDERS; HUMANS; RISK ASSESSMENT; RISK FACTORS; SEPSIS;

EID: 85020513631     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-017-3028-4     Document Type: Article

References (142)

1. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M (2007) Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 110(3):815–825. doi:10.1182/blood-2006-10-050435
2. Franchini M, Mannucci PM (2012) Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 7:24. doi:10.1186/1750-1172-7-24
3. Benjamin RJ, McLaughlin LS (2012) Plasma components: properties, differences, and uses. Transfusion 52(Suppl 1):9S–19S. doi:10.1111/j.1537-2995.2012.03622.x
4. Salunkhe V, van der Meer PF, de Korte D, Seghatchian J, Gutierrez L (2015) Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 52(1):19–34. doi:10.1016/j.transci.2014.12.016
5. Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Guertler L, Ironside JW (2016) Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood Rev 30(1):35–48. doi:10.1016/j.blre.2015.07.004
6. WHO (2011) Global database on blood safety summary report. http://www.who.int/bloodsafety/global_database/GDBS_Summary_Report_
7. World_Bank (2014) New country classifications by income level. http://data.worldbank.org/news/new-country-classifications
8. L’Agence nationale de sécurité du médicament et des produits de santé (ANSM); Rapport d’activité hémovigilance (2015) Available from: http://ansm.sante.fr/var/ansm_site/storage/original/application/27ce3d0739821882c0cd87041b8050a7.pdf
9. Funk M,Lohmann A, Spranger R, Volz-Zang C (2015) Haemovigilance Report of the Paul-Ehrlich-Institut 2013/2014: Assessment of the reports of serious adverse transfusion reactions pursuant to Section 63i AMG (German Medicines Act). http://www.pei.de/SharedDocs/Downloads/vigilanz/haemovigilanz/publikationen/haemovigilance-report-2013-2014.pdf
10. Piccinini V, Facco G, Catalano L, Gentili S, Marano G, Pupella S, Grazzini G, Liumbruno GM Istituto Superiore Di Sanita (ISTISAN). Haemovigilance in Italy. Report 2014 (Accessed at: http://www.iss.it/binary/publ/cont/16_41_web.pdf. http://www.iss.it/binary/publ/cont/16_41_web.pdf)
11. Ministerio de Sanidad, Servicios Sociales e Igualdad de España. Unidad de Hemovigilancia, área Hemoterapia. Subdirección General de Promoción de la Salud y Epidemiología. Hemovigilancia Año 2015. Available from: http://www.msssi.gob.es/profesionales/saludPublica/medicinaTransfusional/hemovigilancia/docs/Informe2015.pdf
12. PHB Bolton-Maggs (Ed) D Poles et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2015 Annual SHOT Report (2016). https://www.shotuk.org/wp-content/uploads/SHOT-2015-Annual-Report-Web-Edition-Final-bookmarked-1.pdf
13. Harvey AR, Basavaraju SV, Chung KW, Kuehnert MJ (2015) Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion 55(4):709–718. doi:10.1111/trf.12918
14. Dorsey KA, Moritz ED, Steele WR, Eder AF, Stramer SL (2013) A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010. Transfusion 53(6):1250–1256. doi:10.1111/j.1537-2995.2012.03904.x
15. Bloodworks_Northwest (2016) Blood component therapy. http://www.bloodworksnw.org/therapy/
16. Hardwick J (2008) Blood processing. International Society of Blood Transfusion (ISBT) Science Series 3:148–176
17. Patient.co.uk (2015) Blood Products for Transfusion
18. WHO (2016) Processing of donated blood. http://www.who.int/bloodsafety/processing/en/
19. WHO (2004) WHO Technical Report, Series No. 924. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. http://www.who.int/bloodproducts/publications/WHO_TRS_924_A4.pdf
20. Funk MB, Heiden M, Volkers P, Lohmann A, Keller-Stanislawski B (2015) Evaluation of risk minimisation measures for blood components - based on reporting rates of transfusion-transmitted reactions (1997-2013). Transfus med Hemother 42(4):240–246. doi:10.1159/000381996
21. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ, German Red Cross NATSG (2008) Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 48(8):1558–1566. doi:10.1111/j.1537-2995.2008.01718.x
22. Velati C, Romano L, Fomiatti L, Baruffi L, Zanetti AR, Group SR (2008) Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 48(10):2205–2213. doi:10.1111/j.1537-2995.2008.01813.x
23. Barjas-Castro ML, Angerami RN, Cunha MS, Suzuki A, Nogueira JS, Rocco IM, Maeda AY, Vasami FG, Katz G, Boin IF, Stucchi RS, Resende MR, Esposito DL, de Souza RP, da Fonseca BA, Addas-Carvalho M (2016) Probable transfusion-transmitted Zika virus in Brazil. Transfusion 56(7):1684–1688. doi:10.1111/trf.13681
24. JPAC (2014) Transfusion handbook (5th edition). http://www.transfusionguidelines.org.uk/transfusion-handbook
25. Vassallo RR, Murphy S (2006) A critical comparison of platelet preparation methods. Curr Opin Hematol 13(5):323–330. doi:10.1097/01.moh.0000239703.40297.a5
26. Food and Drug Administration (FDA) (2002) Guidance for Industry. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm079711.pdf
27. Australian Red Cross Blood Service (2017) Donating after travelling. http://www.donateblood.com.au/eligibility/donating-after-travelling
28. Transfusion.com.au. (2014) http://www.transfusion.com.au/blood_products/storage
29. EDQM (2014) Vision, mission & values. http://www.edqm.eu/en/EDQM-mission-values-604.html
30. EDQM (2010) European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). Symposium on implementation of pathogen reduction technologies for blood components—executive summary
31. EDQM (2013) Guide for the preparation, use and quality assurance of blood components: recommendation no. R (95)15. Council of Europe. https://www.edqm.eu/en/news/guide-preparation-use-and-quality-assurance-blood-components-18th-edition
32. EDQM (2010) European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). The collection, testing and use of blood and blood components in Europe. https://www.edqm.eu/sites/default/files/the_collection_testing_and_use_of_blood_and_blood_components_in_europe_2012_report.pdf
33. EDQM (2012) Blood and blood components: safety, quality, training and ethical matters concerning preparation, use and quality assurance. https://www.edqm.eu/medias/fichiers/blood_and_blood_components_recommendations.pdf
34. Devine DV, Howe D (2010) Processing of whole blood into cellular components and plasma. International Society of Blood Transfusion (ISBT) Science Series 5:78–82
35. Food and Drug Administration (FDA) (2011) Guidance for industry—donors of blood and blood components: notification of donor deferral—small entity compliance guide. Accessed at: https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm257559.htm
36. Kaufman RM (2006) Platelets: testing, dosing and the storage lesion—recent advances. Hematology Am Soc Hematol Educ Program 492–496. doi:10.1182/asheducation-2006.1.492
37. Muller B, Walther-Wenke G, Kalus M, Alt T, Bux J, Zeiler T, Schottstedt V (2014) Routine bacterial screening of platelet concentrates by flow cytometry and its impact on product safety and supply. Vox Sang. doi:10.1111/vox.12214
38. Tholpady A, Monson J, Radovancevic R, Klein K, Bracey A (2013) Analysis of prolonged storage on coagulation factor (F)V, FVII, and FVIII in thawed plasma: is it time to extend the expiration date beyond 5 days? Transfusion 53(3):645–650. doi:10.1111/j.1537-2995.2012.03786.x
39. Kou YT, Pagotto F, Hannach B, Ramirez-Arcos S (2015) Fatal false-negative transfusion infection involving a buffy coat platelet pool contaminated with biofilm-positive Staphylococcus epidermidis: a case report. Transfusion 55(10):2384–2389. doi:10.1111/trf.13154
40. Chhabra P, Payne DC, Szilagyi PG, Edwards KM, Staat MA, Shirley SH, Wikswo M, Nix WA, Lu X, Parashar UD, Vinje J (2013) Etiology of viral gastroenteritis in children <5 years of age in the United States, 2008-2009. J Infect dis 208(5):790–800. doi:10.1093/infdis/jit254
41. Pozzetto B, Garraud O (2016) New viral risks in blood transfusion by 2016. Transfus Clin Biol 23(1):20–27. doi:10.1016/j.tracli.2015.12.004
42. Zhang W, Li L, Deng X, Blumel J, Nubling CM, Hunfeld A, Baylis SA, Delwart E (2016) Viral nucleic acids in human plasma pools. Transfusion. doi:10.1111/trf.13692
43. Bundesärztekammer (2010) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) http://www.bundesaerztekammer.de/aerzte/medizin-ethik/haemotherapie-transfusionsmedizin/haemotherapie/
44. EMA (2011) Guideline on plasma-derived medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109627.pdf
45. Baxter_Healthcare (2014) Advate®; Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000520/WC500022467.pdf
46. Novo_Nordisk (2014) NovoSeven®; Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf
47. Pfizer (2014) BeneFIX®; Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000139/WC500020390.pdf
48. CSL_Behring (2015) Haemate® P Product Information http://www.cslbehring.co.uk/s1/cs/beuk/1241397147289/content/1241397147253/content.htm
49. Novo_Nordisk (2014) Tretten®; Prescribing Information. http://www.tretten-us.com/index.html
50. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group. N Engl J med 328(7):453–459. doi:10.1056/NEJM199302183280701
51. Food and Drug Administration (FDA) (2015) News Release: FDA approves first recombinant von Willebrand factor to treat bleeding episodes. Accessed at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476065.htm
52. Casademunt E, Martinelle K, Jernberg M, Winge S, Tiemeyer M, Biesert L, Knaub S, Walter O, Schroder C (2012) The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol 89(2):165–176. doi:10.1111/j.1600-0609.2012.01804.x
53. Grillberger L, Kreil TR, Nasr S, Reiter M (2009) Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 4(2):186–201. doi:10.1002/biot.200800241
54. Jiang R, Monroe T, McRogers R, Larson PJ (2002) Manufacturing challenges in the commercial production of recombinant coagulation factor VIII. Haemophilia 8(Suppl 2):1–5
55. Calizzani G, Profili S, Candura F, Lanzoni M, Vaglio S, Cannata L, Liumbruno GM, Franchini M, Mannucci PM, Grazzini G (2013) The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfus 11(Suppl 4):s64–s76. doi:10.2450/2013.011s
56. Di Minno G, Canaro M, Ironside JW, Navarro D, Perno CF, Tiede A, Gurtler L (2013) Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica 98(10):1495–1498. doi:10.3324/haematol.2013.084145
57. Farcet MR, Lackner C, Antoine G, Rabel PO, Wieser A, Flicker A, Unger U, Modrof J, Kreil TR (2016) Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes. Transfusion 56(2):383–391. doi:10.1111/trf.13343
58. Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Guertler L, Ironside JW (2015) Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood rev. doi:10.1016/j.blre.2015.07.004
59. Allain JP, Owusu-Ofori AK, Assennato SM, Marschner S, Goodrich RP, Owusu-Ofori S (2016) Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 387(10029):1753–1761. doi:10.1016/S0140-6736(16)00581-X
60. Shepel M, Boyd J, Luider J, Gibb AP (2001) Interaction of Yersinia enterocolitica and Y. pseudotuberculosis with platelets. J med Microbiol 50(12):1030–1038
61. Tolomelli G, Tazzari PL, Paolucci M, Arpinati M, Landini MP, Pagliaro P (2014) Transfusion-related Listeria monocytogenes infection in a patient with acute myeloid leukaemia. Blood Transfus 12(4):611–614. doi:10.2450/2014.0322-13
62. Henschler R, Seifried E, Mufti N (2011) Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus med Hemother 38(1):33–42. doi:10.1159/000324458
63. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H (1991) Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 60(4):207–213
64. Klamroth R, Groner A, Simon TL (2014) Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates. Transfusion 54(5):1406–1417. doi:10.1111/trf.12423
65. Marschner S, Goodrich R (2011) Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus med Hemother 38(1):8–18. doi:10.1159/000324160
66. Schmidt M, Geilenkeuser WJ, Sireis W, Seifried E, Hourfar K (2014) Emerging pathogens - how safe is blood? Transfus med Hemother 41(1):10–17. doi:10.1159/000358017
67. Ambruso DR, Thurman G, Marschner S, Goodrich RP (2009) Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Transfusion 49(12):2631–2636. doi:10.1111/j.1537-2995.2009.02347.x
68. Ciaravino V, McCullough T, Cimino G (2003) The role of toxicology assessment in transfusion medicine. Transfusion 43(10):1481–1492
69. Prowse CV (2013) Component pathogen inactivation: a critical review. Vox Sang 104(3):183–199. doi:10.1111/j.1423-0410.2012.01662.x
70. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP (2008) Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus med rev 22(2):133–153. doi:10.1016/j.tmrv.2007.12.003
71. Seltsam A, Muller TH (2013) Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 162(4):442–454. doi:10.1111/bjh.12403
72. Yarranton H, Lawrie AS, Mackie IJ, Pinkoski L, Corash L, Machin SJ (2005) Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion 45(9):1453–1458. doi:10.1111/j.1537-2995.2005.00551.x
73. Tice RR, Gatehouse D, Kirkland D, Speit G (2007) The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet a light: genotoxicity profile and hazard assessment. Mutat res 630(1–2):50–68. doi:10.1016/j.mrgentox.2007.02.008
74. Knutson F, Osselaer J, Pierelli L, Lozano M, Cid J, Tardivel R, Garraud O, Hervig T, Domanovic D, Cukjati M, Gudmundson S, Hjalmarsdottir IB, Castrillo A, Gonzalez R, Brihante D, Santos M, Schlenke P, Elliott A, Lin JS, Tappe D, Stassinopoulos A, Green J, Corash L (2015) A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 109(4):343–352. doi:10.1111/vox.12287
75. Lozano M, Cid J (2013) Pathogen inactivation: coming of age. Curr Opin Hematol 20(6):540–545. doi:10.1097/MOH.0b013e328365a18f
76. Corten L SL, Liu W, et al (2011) Third International Meeting on Emerging Diseases and Surveillance: Vienna, Austria. Pathogen inactivation of blood components for prevention of transfusion-transmitted emerging infectious diseases: the INTERCEPT Blood System. http://www.interceptbloodsystem.com/resource-center/scientific-publications/intercept-conference-abstracts/2011
77. Musso D, Richard V, Broult J, Cao-Lormeau VM (2014) Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 54(11):2924–2930. doi:10.1111/trf.12713
78. Irsch J, Seghatchian J (2015) Update on pathogen inactivation treatment of plasma, with the INTERCEPT blood system: current position on methodological, clinical and regulatory aspects. Transfus Apher Sci 52(2):240–244. doi:10.1016/j.transci.2015.02.013
79. Aubry M, Richard V, Green J, Broult J, Musso D (2016) Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 56(1):33–40. doi:10.1111/trf.13271
80. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ (2010) Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 150(2):209–217. doi:10.1111/j.1365-2141.2010.08227.x
81. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG, Group SS (2005) Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 45(12):1864–1875. doi:10.1111/j.1537-2995.2005.00639.x
82. Gowland P, Fontana S, Stolz M, Andina N, Niederhauser C (2016) Parvovirus B19 passive transmission by transfusion of intercept(R) blood system-treated platelet concentrate. Transfus med Hemother 43(3):198–202. doi:10.1159/000445195
83. Corash L, Benjamin RJ (2016) The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion 56(Suppl 1):S29–S38. doi:10.1111/trf.13530
84. Osman A, Hitzler WE, Provost P (2016) Peculiarities of studying the effects of pathogen reduction technologies on platelets. Proteomics Clin Appl 10(8):805–815. doi:10.1002/prca.201500124
85. Laughhunn A, Santa Maria F, Broult J, Lanteri MC, Stassinopoulos A, Musso D, Aubry M (2017) Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components. Transfusion. doi:10.1111/trf.13993
86. Winter KM, Johnson L, Kwok M, Vidovic D, Hyland RA, Mufti N, Erickson A, Marks DC (2014) Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion 54(7):1798–1807. doi:10.1111/trf.12545
87. Cancelas JA, Gottschall JL, Rugg N, Graminske S, Schott MA, North A, Huang N, Mufti N, Erickson A, Rico S, Corash L (2017) Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang. doi:10.1111/vox.12500
88. Abonnenc M, Sonego G, Crettaz D, Aliotta A, Prudent M, Tissot JD, Lion N (2015) In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates. Transfusion 55(9):2219–2230. doi:10.1111/trf.13123
89. Faddy HM, Fryk JJ, Prow NA, Watterson D, Young PR, Hall RA, Tolksdorf F, Sumian C, Gravemann U, Seltsam A, Marks DC (2016) Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 56(6 Pt 2):1548–1555. doi:10.1111/trf.13519
90. Cap AP, Pidcoke HF, Keil SD, Staples HM, Anantpadma M, Carrion R Jr, Davey RA, Frazer-Abel A, Taylor AL, Gonzales R, Patterson JL, Goodrich RP (2016) Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion 56(Suppl 1):S6–15. doi:10.1111/trf.13393
91. Ellery B, Mundy L, Juneia V, Braunack-Mayer, Merlin T (2011). Queensland Health-PACT on Technology, Australia and New Zealand. Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0026/427247/wp030.pdf
92. Seghatchian J, Putter JS (2013) Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments, criteria of acceptability and storage lesion. Transfus Apher Sci 49(2):357–363. doi:10.1016/j.transci.2013.07.023
93. Hellstern P, Sachse H, Schwinn H, Oberfrank K (1992) Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 63(3):178–185
94. Hellstern P, Solheim BG (2011) The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus med Hemother 38(1):65–70. doi:10.1159/000323552
95. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW (1992) Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 79(3):826–831
96. Prince AM, Horowitz B, Brotman B (1986) Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1(8483):706–710
97. Lindholm PF, Annen K, Ramsey G (2011) Approaches to minimize infection risk in blood banking and transfusion practice. Infect Disord Drug Targets 11(1):45–56
98. Douet JY, Bujdoso R, Andreoletti O (2015) Leukoreduction and blood-borne vCJD transmission risk. Curr Opin Hematol 22(1):36–40. doi:10.1097/MOH.0000000000000101
99. Lescoutra-Etchegaray N, Jaffre N, Sumian C, Durand V, Correia E, Mikol J, Luccantoni-Freire S, Culeux A, Deslys JP, Comoy EE (2015) Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: a 5-year update. Transfusion. doi:10.1111/trf.12999
100. Neisser-Svae A, Seghatchian J (2015) The state of the art of removal of prion proteins in SD-FFP, by specific prion affinity chromatography and its impact on the hemostatic characteristics of the product. Transfus Apher Sci 52(2):237–239. doi:10.1016/j.transci.2015.02.012
101. The National Cjd Research & Surveillance Unit (NCJDRSU). Creutzfeldt-Jakob Disease Surveillance in the UK. 24th Annual Report (2015). Available at: http://www.cjd.ed.ac.uk/. Accessed March 2017
102. Bougard D, Brandel JP, Belondrade M, Beringue V, Segarra C, Fleury H, Laplanche JL, Mayran C, Nicot S, Green A, Welaratne A, Narbey D, Fournier-Wirth C, Knight R, Will R, Tiberghien P, Haik S, Coste J (2016) Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl med 8(370):370ra182. doi:10.1126/scitranslmed.aag1257
103. Concha-Marambio L, Pritzkow S, Moda F, Tagliavini F, Ironside JW, Schulz PE, Soto C (2016) Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci Transl med 8(370):370ra183. doi:10.1126/scitranslmed.aaf6188
104. Pandey S, Vyas GN (2012) Adverse effects of plasma transfusion. Transfusion 52(Suppl 1):65S–79S. doi:10.1111/j.1537-2995.2012.03663.x
105. Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR (2016) A randomized trial of factor VIII and neutralizing antibodies in hemophilia a. N Engl J med 374(21):2054–2064. doi:10.1056/NEJMoa1516437
106. Hashemi SM, Other J, Another C (2015) Risk for inhibitor development in severe hemophilia A is not associated with FVIII product class or with high von-Willebrand content—oral presentation at ISTH 2015
107. Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Makipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM (2013) Factor VIII products and inhibitor development in severe hemophilia A. N Engl J med 368(3):231–239. doi:10.1056/NEJMoa1208024
108. Piquet Y, Janvier G, Selosse P, Doutremepuich C, Jouneau J, Nicolle G, Platel D, Vezon G (1992) Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 63(4):251–256
109. Atance R, Pereira A, Ramirez B (2001) Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41(12):1548–1552
110. Barz D (1994) Detection of antigen structures in blood cells in various prepared plasma transfusions. Anaesthesiol Reanim 19(6):155–158
111. Dewachter P, Castro S, Nicaise-Roland P, Chollet-Martin S, Le Beller C, Lillo-le-Louet A, Mouton-Faivre C (2011) Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 106(5):687–689. doi:10.1093/bja/aer009
112. Nubret K, Delhoume M, Orsel I, Laudy JS, Sellami M, Nathan N (2011) Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue. Transfusion 51(1):125–128. doi:10.1111/j.1537-2995.2010.02800.x
113. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ (2003) Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 121(5):778–785
114. Franchini M, Coppola A, Rocino A, Zanon E, Morfini M, Accorsi A, Aru AB, Biasoli C, Cantori I, Castaman G, Cesaro S, Ciabatta C, De Cristofaro R, Delios G, Di Minno G, D’Inca M, Dragani A, Ettorre CP, Gagliano F, Gamba G, Gandini G, Giordano P, Giuffrida G, Gresele P, Latella C, Luciani M, Margaglione M, Marietta M, Mazzucconi MG, Messina M, Molinari AC, Notarangelo LD, Oliovecchio E, Peyvandi F, Piseddu G, Rossetti G, Rossi V, Santagostino E, Schiavoni M, Schinco P, Serino ML, Tagliaferri A, Testa S (2014) Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. Haemophilia 20(2):e128–e135. doi:10.1111/hae.12334
115. Shepard DS, Undurraga EA, Betancourt-Cravioto M, Guzman MG, Halstead SB, Harris E, Mudin RN, Murray KO, Tapia-Conyer R, Gubler DJ (2014) Approaches to refining estimates of global burden and economics of dengue. PLoS Negl Trop Dis 8(11):e3306. doi:10.1371/journal.pntd.0003306
116. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD (2016) The global economic burden of dengue: a systematic analysis. Lancet Infect dis. doi:10.1016/S1473-3099(16)00146-8
117. Liumbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C, Macini P, Tomasini I, Zucchelli P, Silvestri AR, Sambri V, Pupella S, Catalano L, Piccinini V, Calizzani G, Grazzini G (2008) The chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 6(4):199–210
118. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME, West Nile Virus Transmission Investigation T (2003) Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J med 349(13):1236–1245. doi:10.1056/NEJMoa030969
119. Macciocchi D, Lanini S, Vairo F, Zumla A, Figueiredo LT, Lauria FN, Strada G, Brouqui P, Puro V, Krishna S, Kremsner P, Scognamiglio P, Kohler C, Nicastri E, Di Caro A, Cieri RM, Ioannidis JP, Kobinger G, Burattini MN, Ippolito G (2016) Short-term economic impact of the Zika virus outbreak. New Microbiol 39(4):287–289
120. Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, Roddie H, Pelly J, Docherty A, Sherman C, Lin L, Propst M, Corash L, Prowse C (2011) A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 153(3):393–401. doi:10.1111/j.1365-2141.2011.08635.x
121. Kleinman S, Reed W, Stassinopoulos A (2013) A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 53(7):1603–1618. doi:10.1111/j.1537-2995.2012.03928.x
122. SaBTO: Advisory Committee on the Safety of Blood, Tissues and Organs. Pathogen Inactivation of Platelets: Report of the SaBTO Working Group (2014). Accessed at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/324354/SaBTO_platelets_report.pdf
123. Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, Muncunill J, Serret C, Serra N, Sedeno M (2014) Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 54(1):158–168. doi:10.1111/trf.12232
124. Moeremans K, Warie H, Annemans L (2006) Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 16(1):17–30. doi:10.1111/j.1365-3148.2006.00644.x
125. Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U (2005) Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 15(5):379–387. doi:10.1111/j.1365-3148.2005.00609.x
126. McCullough J, Goldfinger D, Gorlin J, Riley WJ, Sandhu H, Stowell C, Ward D, Clay M, Pulkrabek S, Chrebtow V, Stassinopoulos A (2015) Cost implications of implementation of pathogen-inactivated platelets. Transfusion 55(10):2312–2320. doi:10.1111/trf.13149
127. Kwon SY, Kim IS, Bae JE, Kang JW, Cho YJ, Cho NS, Lee SW (2014) Pathogen inactivation efficacy of Mirasol PRT system and intercept blood system for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 107(3):254–260. doi:10.1111/vox.12158
128. Food and Drug Administration (FDA) (2007) Guidance for Industry and FDA Review Staff: Collection of Platelets by Automated Methods. Accessed at: https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm073382.htm. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm073382.htm
129. American Association of Blood Banks (AABB) (2015) Blood and Blood Components. Accessed at: http://www.aabb.org/advocacy/regulatorygovernment/bloodcomponents/Pages/default.aspx
130. Lautenbach DM, Christensen KD, Sparks JA, Green RC (2013) Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet 14:491–513. doi:10.1146/annurev-genom-092010-110722
131. Smit AK, Keogh LA, Hersch J, Newson AJ, Butow P, Williams G, Cust AE (2016) Public preferences for communicating personal genomic risk information: a focus group study. Health Expect 19(6):1203–1214. doi:10.1111/hex.12406
132. Calman KC, Royston GH (1997) Risk language and dialects. BMJ 315(7113):939–942
133. Meybohm P, Richards T, Isbister J, Hofmann A, Shander A, Goodnough LT, Munoz M, Gombotz H, Weber CF, Choorapoikayil S, Spahn DR, Zacharowski K (2016) Patient blood management bundles to facilitate implementation. Transfus med rev. doi:10.1016/j.tmrv.2016.05.012
134. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A, Treatment Guidelines Working Group on Behalf of The World Federation Of H (2013) Guidelines for the management of hemophilia. Haemophilia 19(1):e1–47. doi:10.1111/j.1365-2516.2012.02909.x
135. Bundesärztekammer (2008) Cross-sectional guidelines for therapy with blood components and plasma derivatives, 4th edn (revised). http://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/Querschnittsleitlinie_Gesamtdokument-englisch_07032011.pdf
136. Rocino A, Coppola A, Franchini M, Castaman G, Santoro C, Zanon E, Santagostino E, Morfini M, Italian Association of Haemophilia Centres Working P (2014) Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 12(4):575–598. doi:10.2450/2014.0223-14
137. Associazione Italiana Centri Emofilia (AICE) (2015) Informed consent form for haemophilia treaters of Italy (Consenso Informato e informativa). Accessed at: http://www.aiceonline.org/
138. Hemoterapia SEdHy (2012) Estándares en Transfusión Sanguínea – Fundacion CAT (4th edition) http://www.catransfusion.es/media/upload/arxius/documentos/ANEXO_ESTANDARES_2012.pdf
139. Hospital SEU (2015) Informed consent form for transfusion
140. Friedman M, Arja W, Batra R, Daniel S, Hoehn D, Paniz AM, Selegean S, Slova D, Srivastava S, Vergara N (2012) Informed consent for blood transfusion: what do medicine residents tell? What do patients understand? Am J Clin Pathol 138(4):559–565. doi:10.1309/AJCP2TN5ODJLYGQR
141. American Association of Blood Banks (AABB) (2009) Standards for blood banks and transfusion services, 26th ed. Accessed at: http://www.aabb.org/
142. Vossoughi SR, Macauley R, Sazama K, Fung MK (2015) Attitudes, practices, and training on informed consent for transfusions and procedures: a survey of medical students and physicians. Am J Clin Pathol 144(2):315–321. doi:10.1309/AJCPP85EXSGZORYZ